Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

From August through November 2006, the number of febrile patients increased in 4 major hospitals in the Terai region of Nepal: Nepalgunj Medical College, Bheri Zonal Hospital in Nepalgunj, Tribhuban Hospital in Dang, and Narayani subregional hospital in Birgunj. Patients with severe symptoms were referred to Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, for diagnosis and treatment. The clinical features in most patients were consistent with signs of DF, but some patients showed signs (high fever, rash, ecchymosis, epistaxis, positive tourniquet test, liver dysfunction, and thrombocytopenia [platelet count <100,000/mm3]) consistent with the World Health Organization (WHO) definition of DHF. Ascites and plural effusion developed in 2 patients. Blood specimens were collected from all patients at the time of admission to the local hospitals. Particle agglutination (PA) assay (Pentax Ltd, Tokyo, Japan) (5) and immunoglobulin (Ig) M–capture ELISA (Dengue/JE IgM Combo ELISA kit, Panbio Ltd, Brisbane, Queensland, Australia) were performed. Dengue virus–specific IgM was detected in 11 patients who had fever, headache, and rash (Table). Each of these patients had negative results for Japanese encephalitis virus–specific IgM. Of the 11 patients, 10 had no history of travel to India or other dengue-endemic countries. DF or DHF was initially diagnosed for 7 patients, and viral encephalitis, typhoid fever, or viral fever was diagnosed for others without serologic tests. Reverse transcription–PCR and virus isolation were performed at Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan, but the dengue virus genome was not detected, and no virus was isolated, likely because sample collection was delayed and the sample was transported to Japan in a deteriorated condition.

DF/DHF have been considered to be a possible public health threat to Nepal because DF/DHF epidemics have occurred recently in India and Pakistan, which reported several thousand cases and >100 deaths (6). The first DF case in Nepal was reported in 2004 (7). Further, the first DENV-2 strain of Nepal origin was isolated from a Japanese traveler who visited Nepal and in which DF developed after the patient returned to Japan. The isolated DENV-2 (GenBank accession no. AB194882) was 98% homologous with DENV-2 isolated in India (8). The prevalence of dengue virus antibody was reported to be 10.4% in the southwestern region of Nepal (9). These reports suggest that dengue virus has been circulating in Nepal for several years. Thus, DF/DHF has likely been misdiagnosed and illness caused by dengue virus underestimated in Nepal. In contrast, Japanese encephalitis has been a public health problem in southwestern region of Nepal, and large epidemics have occurred almost every year since 1978 (10). Nepal has no dengue surveillance programs, and health professionals do not usually consider dengue as a differential diagnosis.

The emergence occurred in the lowland Terai belt region, which borders the state of Bihar, India. The Aedes mosquito is known to persist in this region. The emerging DENV-2 is likely to have been introduced into Nepal from India.

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.